Member Directory
Our award-winning life sciences team is led by highly-ranked lawyers who advise companies in the biotech, pharmaceutical, diagnostics, veterinary and healthcare sectors. We add value with lawyers who understand the science from their degree subjects, and understand your business, having worked in-house for life science companies, or with them for many years. We act for companies, at all stages of their life cycle, including global pharmaceutical companies, larger plcs and SMEs, together with research organisations, venture capital funds and universities. 'Impressive IP practice acting for life sciences businesses, universities and their spinoffs… Recommended for licence and research agreements.' - Chambers 2017.
Pharma International provides global pharmaceutical regulatory consultancy services, with an emphasis on the emerging markets. Fully licensed by Swissmedic, Pharma International is authorised to trade in biotechnology, pharmaceuticals and medical devices internationally – as well as providing Swiss Qualified Person services. Seminars on regulatory affairs, especially Asia including ASEAN, China, Korea and India, are conducted regularly and can be adapted to in-house requirements.
Regulatory Consultancy
PharmaMedic provides a comprehensive outsourced virtual medical and regulatory affairs service for start-ups, mid to late-stage biopharma, as well as consumer health organisations, medical device companies, and academic centres. We deliver our virtual medical and regulatory affairs solutions through a team of experienced pharmaceutical consultants. We provide a range of flexible services supporting start-ups, product launches, and large pharma teams.
For more information visit our website https://pharmamedic.co/
Download our capabilities brochure here https://pharmamedic.co/wp-content/uploads/2020/09/PMC-Capabilities.pdf
Watch our Member Showcase Video https://bit.ly/3rzlfvd
Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products. With over 15,000 employees, and operations in China, the U.S., and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, visit: https://www.pharmaron.com
PhoreMost™ is focused on bringing more effective and affordable targeted medicines to patients. To achieve this aim, PhoreMost is developing a next-generation phenotypic screening technology that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the company's proprietary Protein Interference (PROTEINi®) technology, PhoreMost has developed SITESEEKER®; a platform that can systematically unmask cryptic druggable sites in the human genome and then link them to useful therapeutic functions in a live-cell context.
PASM offers clinical trial support services, with special expertise in helping SMEs. Projects undertaken span planning a clinical trials program to meet a regulatory strategy, through to designing and implementing outsourcing strategies to fit the company's needs.